Biodesix’s losses compound in fourth quarter
BOULDER — Biodesix Inc. (Nasdaq: BDSX) grew its year-over-year losses by nearly three-fold in the fourth quarter and matched Wall Street analysts’ predictions for a tough earnings period for the Boulder pharmaceutical diagnostics company.
Losses on the quarter were nearly $13.3 million and more than $43 million for the full 2021 fiscal year, up from losses of about $31 million the previous year.
The fourth-quarter result represents an earnings per share loss of 49 cents, slightly less than the Zacks Consensus Estimate of 50 cents.
SPONSORED CONTENT
The many benefits of simple, coordinated healthcare
Kaiser Permanente combines health care and coverage in one connected system to maximize employee health and minimize employer costs.
Revenues for the quarter and full fiscal year were $7.2 million and $54.5 million, respectively.
Part of the reason for the fourth-quarter slide compared with the same period last year was due to a drop in COVID-19 testing revenue as fewer people sought out Biodesix’s lab-based testing and more relied on at-home products.
Operating expenses for the quarter and year were up 9% and 40%, reflecting a doubling of the company’s lung-focused sales force.
Biodesix’s stock ended Monday trading down 3.57%. Over the last year, the stock has shed 90.60% of its value.
In 2022, Biodesix estimates that it will record sales between $37.5 million to $39.5 million.
